In October 2020, a press release from Cyclerion Therapeutics announced interesting results from a Phase 1 translational pharmacology study on IW-6463, a novel sGC stimulator that is being developed for different cognitive disorders, including AD. Here, SGCB is linked to Cognitive impairment.